Biovica International AB Class B (BIOVIC.B) AI Stock Analysis

• Market Cap: €160.49M
• Dividend Yield: N/A
• Average Volume (3M): 324.11K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: 31.03%
• EPS Growth: 55.25%
• Country: SE
• Employees: 26
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 275,289,060
• 10 Day Avg. Volume: 299,971
• 30 Day Avg. Volume: 324,106
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: kr0.50 ▲(2.04% Upside)

Biovica International AB Class B is facing significant financial challenges with ongoing losses and negative cash flows, which are the most impactful factors. The technical analysis indicates a bearish trend, and the valuation is unattractive due to a negative P/E ratio. These factors collectively result in a low overall stock score.

Biovica International AB Class B Business Overview & Revenue Model

Company Description

Biovica International AB Class B (BIOVIC.B) is a biotechnology company based in Sweden, specializing in the development of diagnostic solutions for cancer. The company focuses on improving the management of cancer treatment through its innovative blood test products that enable the monitoring of treatment efficacy and disease progression. Biovica's core product, DiviTum, is designed to measure the levels of a specific biomarker in the blood, providing valuable information to oncologists and healthcare providers in making informed treatment decisions.

How the Company Makes Money

Biovica generates revenue primarily through the commercialization of its diagnostic products, particularly the DiviTum assay. The company sells its tests to hospitals, laboratories, and healthcare providers, charging fees for each test conducted. Additionally, Biovica may engage in partnerships with pharmaceutical companies and research institutions, which can involve licensing agreements, joint research initiatives, and collaborative studies. These partnerships not only provide additional revenue streams but also enhance the company's market reach and credibility in the oncology diagnostics field. The growth in demand for precise cancer monitoring solutions and the increasing emphasis on personalized medicine further bolster Biovica's potential for generating income.

Biovica International AB Class B Financial Statement Overview

Summary

Biovica International AB Class B shows encouraging revenue growth, yet faces ongoing profitability challenges. The balance sheet remains stable with low leverage, but cash flow pressures and consistent losses highlight the need for strategic improvements. The company’s financial health is at risk without addressing operational inefficiencies and achieving sustainable profitability.

Income Statement

Biovica International AB Class B shows a substantial revenue growth from SEK 2,045,000 in 2022 to SEK 8,619,000 in 2025, indicating a positive trajectory. However, the company operates with negative EBIT and net income, showing significant losses consistently over the years. Margins remain negative with EBIT and EBITDA margins deteriorating, indicating challenges in profitability despite revenue growth.

Balance Sheet

The company maintains a solid equity base with a high equity ratio, although it has declined as liabilities increased. The debt-to-equity ratio remains low, signaling manageable leverage. However, the negative net income contributes to a negative ROE, reflecting profitability issues. Overall, while the balance sheet is stable, profitability needs improvement.

Cash Flow

Operating cash flows are negative and have worsened over time, reflecting operational challenges. Free cash flow remains negative, with no significant improvements. The company relies on financing activities to sustain operations, which may not be sustainable in the long run without profitability improvements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.62M	8.62M	7.29M	3.38M	2.04M	2.08M
Gross Profit	8.08M	8.08M	6.88M	4.62M	4.67M	5.27M
EBITDA	-77.12M	-76.22M	-119.51M	-105.96M	-53.47M	-36.56M
Net Income	-87.62M	-87.62M	-124.82M	-110.49M	-60.00M	-39.48M
Balance Sheet
Total Assets	64.95M	64.95M	131.41M	172.29M	151.63M	192.65M
Cash, Cash Equivalents and Short-Term Investments	24.41M	24.41M	79.41M	114.33M	89.79M	145.36M
Total Debt	4.65M	4.65M	7.83M	10.45M	13.25M	2.42M
Total Liabilities	21.74M	21.74M	34.77M	33.65M	27.54M	9.99M
Stockholders Equity	43.21M	43.21M	96.64M	138.63M	124.09M	182.66M
Cash Flow
Free Cash Flow	-85.66M	-85.65M	-114.72M	-97.42M	-55.52M	-37.97M
Operating Cash Flow	-85.37M	-85.37M	-114.58M	-94.64M	-52.13M	-34.41M
Investing Cash Flow	-287.00K	-287.00K	-585.00K	-2.78M	-3.40M	-3.56M
Financing Cash Flow	30.93M	30.93M	79.50M	122.01M	-136.00K	142.66M

Biovica International AB Class B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.49
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOVIC.B, the sentiment is Negative. The current price of 0.49 is below the 20-day moving average (MA) of 0.57, below the 50-day MA of 0.60, and below the 200-day MA of 0.91, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 15.91 is Positive, neither overbought nor oversold. The STOCH value of 24.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOVIC.B.

Biovica International AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALZ	―	kr158.15M	―	-20.22%	―	-67.00%	23.63%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXTCL	―	kr100.70M	―	-52.45%	―	2.56%	52.76%
NICA	―	€114.86M	-2.28	-294.38%	―	186.74%	73.17%
BIOVIC.B	―	€160.49M	-0.80	-146.43%	―	31.03%	55.25%
BIOSGN	―	kr110.37M	―	-101.53%	―	―	65.16%